TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01911520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex. 4 mg/kg
Description: Patients receive 4 mg/kg Sugammadex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex. 4 mg/kg
Description: Patients receive 4 mg/kg Sugammadex.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring.
Description: Neuromuscular monitoring using a TOF watch SX (Organon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of residual curarization .
Description: Every 30 min, during the first 2 hours after the end of the surgery.
Study: NCT04166032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alertgy non-invasive continuous glucose monitoring device (ANICGM)
Description: Alertgy non-invasive continuous glucose monitoring device (ANICGM)
Study: NCT04286802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salt-meter
Description: Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Program dietary education by certified dietician who did not know the patients arm allocation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Program dietary education by certified dietician who did not know the patients arm allocation.
Study: NCT00548184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine
Description: Hormonal Therapy
Study: NCT03965377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Safety Hero Computer Game
Description: Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
Study: NCT04610476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Ixekizumab s.c. 1x 80 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
Study: NCT00594217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone suspension, single 100 mg oral dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study: NCT03209284

Intervention type: PROCEDURE
Intervention: transcrestal sinus floor elevation
Description: augmentation procedure with xenograft

Intervention type: PROCEDURE
Intervention: transcrestal sinus floor elevation
Description: augmentation procedure with xenograft
Study: NCT03611439

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReBuilder
Description: 8-component botanical dietary supplement
Study: NCT01566396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A3F
Description: A3F fractional RF treatments for facial wrinkles
Study: NCT01864174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Study: NCT03611439

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo Capsule
Study: NCT00355316

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study: NCT03784183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS)
Description: CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS)
Description: CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS)
Description: CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
Study: NCT00245271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
Study: NCT01864174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Metformin XR
Study: NCT02317549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02410343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
Study: NCT02072616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic adenocarcinoma diagnosis
Study: NCT00087802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/Eloxatin (GEMOX)
Description: GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]
Study: NCT01864174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Metformin IR
Study: NCT02739997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole 500 mg
Description: metronidazole 500 mg administered as an IV infusion
Study: NCT00816504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Study: NCT02290171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity groups
Description: Children attend to activity groups weekly during the intervention periode.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based dietary counselling
Description: Parents attend to four sessions of group based dietary counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual counselling
Description: Parents attend to individual counselling focusing on parental skills and family structure
Study: NCT00887263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 3 mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg TID
Study: NCT01769183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate ophthalmic solution 0.2%
Description: Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
Study: NCT04682145

Intervention type: DRUG
Intervention: Turoctocog alfa pegol
Description: Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
Study: NCT00267592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT) 5 days a week +

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide(TMZ) 75mg
Description: temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant TMZ 200mg
Description: adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
Study: NCT01732172

Intervention type: OTHER
Group type: OTHER
Intervention: Sperm sample
Description: Sperm sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sperm sample
Description: Sperm sample
Study: NCT00155545

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Motion analysis of patients
Study: NCT00857623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once daily
Study: NCT01581450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 35%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: 50%
Study: NCT04759885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 low dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Study: NCT00087802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin/paclitaxel (CP)
Description: CP \[carboplatin/paclitaxel - 21 day cycle\]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]
Study: NCT04759885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 medium dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: NTC015 high dose
Description: Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase III: NTC015 selected dose
Description: Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)
Description: The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure.
Study: NCT03141047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifespan Integration
Description: A protocol based psychological treatment method
Study: NCT03384602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dalcroze Eurhythmics Program
Description: music-based multi-task exercise in group setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise strength program
Description: simple strength exercise program to perform individually at home
Study: NCT01799083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cell
Description: Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
Study: NCT00888355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo to losartan tablet q.a.m. , for 12 weeks
Study: NCT00085280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03062657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE LP™ Cervical Disc
Description: The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
Study: NCT03403192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-Blocker
Description: The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-Blocker
Description: The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLT
Description: A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLT
Description: A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
Study: NCT03603652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
Study: NCT03566940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cIPV
Description: Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
Study: NCT02660099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Description: The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
Study: NCT02572167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg by intravenous (IV) infusion for up to 4 cycles